GPBAR1 and metabolic dysfunction-associated steatotic liver disease: This impairs farnesoid X receptor (FXR) and Takeda G‐protein‐coupled receptor 5 (TGR5) signaling, thereby increasing gut permeability, promoting endotoxin translocation, and exacerbating NAFLD via enhanced hepatic steatosis and fibrosis (Li et al. 2022; Yang and Zhang 2021).